Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Has Average Price Target of $34.79

Posted by Brian Himes on Oct 26th, 2026

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $34.79.

Several research analysts recently weighed in on NRIX shares. Royal Bank Of Canada dropped their price target on Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 13th. Robert W. Baird raised their price objective on Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 13th. Oppenheimer lifted their target price on Nurix Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, October 13th. Truist Financial lowered their target price on Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, October 13th. Finally, BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Nurix Therapeutics in a report on Friday, July 10th.

Read Our Latest Stock Report on NRIX

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 4,356 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00. Following the transaction, the insider directly owned 117,227 shares of the company’s stock, valued at approximately $2,930,675. The trade was a 3.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julia Gregory sold 22,583 shares of the company’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $23.40, for a total transaction of $528,442.20. Following the completion of the transaction, the director owned 10,750 shares in the company, valued at approximately $251,550. This represents a 67.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,407 shares of company stock valued at $1,083,206. Corporate insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On Nurix Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Trails Edge Capital Partners LP purchased a new stake in shares of Nurix Therapeutics during the second quarter worth $38,166,318. Bank of New York Mellon Corp acquired a new stake in Nurix Therapeutics during the second quarter valued at $6,614,000. Man Group plc purchased a new position in Nurix Therapeutics in the second quarter valued at about $2,076,000. Bank of America Corp DE purchased a new position in Nurix Therapeutics in the second quarter valued at about $20,429,000. Finally, Perceptive Advisors LLC grew its stake in Nurix Therapeutics by 4.4% in the first quarter. Perceptive Advisors LLC now owns 3,710,877 shares of the company’s stock valued at $57,519,000 after purchasing an additional 155,000 shares in the last quarter.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock opened at $25.34 on Friday. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of 10.97 and a beta of 1.82. Nurix Therapeutics has a twelve month low of $10.38 and a twelve month high of $28.23. The business’s 50 day simple moving average is $25.01 and its 200-day simple moving average is $21.55.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last released its quarterly earnings results on Monday, October 12th. The company reported $4.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $5.33. The company had revenue of $673.06 million during the quarter, compared to analysts’ expectations of $24.35 million. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. Sell-side analysts predict that Nurix Therapeutics will post 1.14 earnings per share for the current year.

About Nurix Therapeutics

(Get Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.